Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non‐small cell lung cancer

K. M.W. Pisters, M. G. Kris, R. J. Gralla, B. Hilaris, P. M. McCormack, M. S. Bains, N. Martini

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

This prospective randomized trial was performed to determine whether postoperative chemotherapy with vindesine and cisplatin could lengthen time to progression and overall survival in stage III (T1‐3N2MO) non‐small cell lung cancer (NSCLC) patients. Seventy‐two patients were entered; 36 were randomized to receive chemotherapy. Patients were stratified by extent of resection (complete vs. incomplete) and histology (squamous vs. nonsquamous). All had surgery and mediastinal irradiation 6–7 weeks post‐thoracotomy. Incompletely resected patients had intraoperative 125I and/or 192Ir implantation. Vindesine (3 mg/m2) weekly × 5, then every 2 weeks × 8, and cisplatin (120 mg/m2) days 1, 29, 71, 113 were planned for those randomized to chemotherapy. No difference in time to progression (median 9.2 months for radiation + chemotherapy vs. 9.0 months for radiation, P = 0.35) or overall survival (16.3 months for radiation + chemotherapy vs. 19.1 months for radiation, P = 0.42) was found. Postoperative vindesine and cisplatin did not prolong time to progression or survival in this population of stage III NSCLC. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalJournal of Surgical Oncology
Volume56
Issue number4
DOIs
StatePublished - Aug 1994

Keywords

  • adjuvant chemotherapy
  • cisplatin
  • non‐small cell lung cancer
  • postoperative therapy
  • radiation
  • vindesine

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non‐small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this